COVID-19 与意义未明的单克隆丙种球蛋白血症患者中严重感染和死亡的危险因素。
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance.
机构信息
Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
出版信息
Blood. 2022 Nov 3;140(18):1997-2000. doi: 10.1182/blood.2022017616.
Abstract
Two Letters to address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.
摘要
两封关于血液系统疾病前驱患者感染 COVID-19 风险的信。在第一篇文章中，Miller 及其同事报告了中等程度的克隆性造血（CHIP）是否与 COVID-19 的不良结局相关，发现 CHIP 与 28 天死亡率之间无关联，同时提供了间接关联白细胞介素 6 信号和患者结局的数据。在第二篇文章中，Ho 及其同事研究了 COVID-19 合并意义未明的单克隆丙种球蛋白血症（MGUS）患者的结局，报告称四分之一的患者有严重感染，多变量分析显示，如果存在免疫缺陷，不良结局更有可能发生。
相似文献
1
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance.
Blood. 2022 Nov 3;140(18):1997-2000. doi: 10.1182/blood.2022017616.
2
Monoclonal gammopathy of uncertain significance.
Med Clin (Barc). 2023 Sep 8;161(5):217-224. doi: 10.1016/j.medcli.2023.05.006. Epub 2023 Jun 15.
3
Monoclonal Gammopathy of Undetermined Significance.
Ann Intern Med. 2022 Dec;175(12):ITC177-ITC192. doi: 10.7326/AITC202212200. Epub 2022 Dec 13.
4
[Cerebrospinal fluid proteins in 3 cases of polyneuritis complicating plasma cell dyscrasias].
Riv Neurobiol. 1984 Apr-Sep;30(2-3):240-8.
5
[Nephropathies in the course of plasma cell disorders].
Przegl Lek. 1995;52(3):97-9.
6
Monoclonal gammopathy and rheumatic diseases.
Acta Reumatol Port. 2014 Jan-Mar;39(1):12-8.
7
Metastatic breast cancer and monoclonal gammopathy of undetermined significance resembling multiple myeloma.
BMJ Case Rep. 2023 Jun 22;16(6):e254016. doi: 10.1136/bcr-2022-254016.
8
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Blood. 2012 Jun 7;119(23):5359-66. doi: 10.1182/blood-2011-11-387324. Epub 2012 Feb 21.
9
Post-Transplant Monoclonal Gammopathy of Renal Significance: A Case Report.
Transplant Proc. 2023 Dec;55(10):2301-2303. doi: 10.1016/j.transproceed.2023.09.005. Epub 2023 Nov 29.
10
Single monoclonal spike characterized as double monoclonal gammopathy in a patient with multiple myeloma: A rare finding.
Indian J Pathol Microbiol. 2024 Jan-Mar;67(1):192-194. doi: 10.4103/ijpm.ijpm_904_21.
引用本文的文献
1
Advanced disease and CD8 TEMRA cells predict severe infections in multiple myeloma.
Front Immunol. 2025 Feb 12;16:1532645. doi: 10.3389/fimmu.2025.1532645. eCollection 2025.
2
Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health.
Geroscience. 2025 Feb;47(1):745-779. doi: 10.1007/s11357-024-01487-4. Epub 2025 Jan 7.
3
Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease.
Ann Hematol. 2023 Oct;102(10):2857-2864. doi: 10.1007/s00277-023-05350-y. Epub 2023 Jul 12.
4
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173.
5
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.
Blood Cancer J. 2022 Nov 24;12(11):160. doi: 10.1038/s41408-022-00752-z.
本文引用的文献
1
Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders.
Blood. 2022 Aug 18;140(7):782-785. doi: 10.1182/blood.2022016317.
2
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2027160. doi: 10.1080/21645515.2022.2027160. Epub 2022 Feb 3.
3
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.
Blood. 2022 Mar 3;139(9):1409-1412. doi: 10.1182/blood.2021014989.
4
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination.
JAMA Oncol. 2022 Feb 1;8(2):201-202. doi: 10.1001/jamaoncol.2021.5942.
5
Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.
Blood Cancer J. 2021 Dec 1;11(12):191. doi: 10.1038/s41408-021-00580-7.
6
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study.
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359. doi: 10.1016/S2213-8587(21)00089-9. Epub 2021 Apr 28.
7
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
8
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.
Blood Adv. 2020 Dec 8;4(23):5966-5975. doi: 10.1182/bloodadvances.2020003170.
Zotero 插件